Protagenic Therapeutics Faces Nasdaq Delisting Due to Compliance Issues

MT Newswires Live
2025/11/28

Protagenic Therapeutics (PTIX) said Thursday it received a Nasdaq notice for failing to meet the minimum $2.5 million stockholders' equity requirement and for not filing its quarterly report on time.

The company said Nasdaq flagged its recently reported equity levels and the delayed Form 10-Q for the quarter ended Sept. 30, 2025. Because the company had only recently regained compliance and remains under a mandatory panel monitoring period, Nasdaq has moved to delist its shares.

The company said it will request a hearing, which automatically halts any suspension for 15 days, and will also seek an additional stay while the panel reviews its case.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10